Morgan Stanley
FBLG icon

Morgan Stanley’s FibroBiologics FBLG Stock Holding History

Morgan Stanley’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$7 – 8499
2025
Q3 		$7 Sell
1
-309
-100% -$3.7K ﹤0.01% 8115
2025
Q2 		$3.86K Sell
310
-1,523
-83% -$27.5K ﹤0.01% 7098
2025
Q1 		$33K Sell
1,833
-1,036
-36% -$29.6K ﹤0.01% 6411
2024
Q4 		$115K Sell
2,869
-656
-19% -$35.2K ﹤0.01% 6007
2024
Q3 		$218K Buy
3,525
+2,351
+200% +$156K ﹤0.01% 5723
2024
Q2 		$117K Buy
+1,174
New +$224K ﹤0.01% 5906

Other funds holding FBLG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
ANTB
AMG National Trust Bank Greenwood Village, Colorado $4.88B AUM 24.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley's FBLG Position: Q4 2025 in Review

Morgan Stanley sold out of FibroBiologics (FBLG) in Q4 2025, closing a stake of 1 share — an estimated $7 sold.

Morgan Stanley first reported a position in FBLG in Q2 2024 and held it in 6 quarters. The position peaked at $218K in Q3 2024. 45 funds tracked by Wall St. Rank hold FBLG as of Q4 2025.

  • Morgan Stanley reported no remaining FibroBiologics position as of Q4 2025 after selling out during the quarter.
  • Morgan Stanley sold 1 FibroBiologics share in Q4 2025, an estimated $7.
  • Morgan Stanley first reported a position in FibroBiologics in Q2 2024 and held it in 6 quarters.
  • Morgan Stanley's FibroBiologics position peaked at $218K in Q3 2024.
  • 45 funds tracked by Wall St. Rank held FibroBiologics as of Q4 2025.

Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.